4-(4-(吡啶-4-基)苯基)噻吩-2-羧酸甲酯 | 820224-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(4-(吡啶-4-基)苯基)噻吩-2-羧酸甲酯
• 英文名称: methyl 4-[4-(pyridin-4-yl)phenyl]thiophen-2-carboxylate
• 英文别名: Methyl 4-(4-(pyridin-4-YL)phenyl)thiophene-2-carboxylate；methyl 4-(4-pyridin-4-ylphenyl)thiophene-2-carboxylate
• CAS: 820224-07-5
• 化学式: C₁₇H₁₃NO₂S
• 分子量: 295.362
• InChiKey: VPPXNTGGIBGLHT-UHFFFAOYSA-N

物化性质

• 沸点：
  464.1±40.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-(吡啶-4-基)苯基)噻吩-2-羧酸甲酯 在 lithium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以44.5%的产率得到4-[4-(pyridin-4-yl)phenyl]thiophen-2-carboxylic acid
  参考文献：
  名称：

  [EN] MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS
  [FR] INHIBITEURS DE METALLOPROTEINASE MATRICIELLE ET PROCEDES D'IDENTIFICATION DE COMPOSES CHEFS DE FILE

  摘要：

  公开号：

  WO2004014381A2
• 作为产物：
  描述：

  4-(4-溴苯基)-2-噻吩羧酸甲酯 、 吡啶-4-硼酸 在 potassium phosphate 、 四(三苯基膦)钯 作用下， 以 乙二醇二甲醚 为溶剂， 生成 4-(4-(吡啶-4-基)苯基)噻吩-2-羧酸甲酯
  参考文献：
  名称：

  Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors

  摘要：

  A new class of MMP-12 inhibitors was discovered and optimized using structure-based drug design methods. Modeling studies using a known MMP-12 crystal structure identified a new interaction mode for these new MMP-12 inhibitors. Further optimization resulted in the discovery of a compound displaying nanomolar activity against MMP-12 and which was co-crystallized with MMP-12. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.079

文献信息

• Matrix metalloproteinase inhibitors and methods for identification of lead compounds
  申请人：——

  公开号：US20040171543A1

  公开（公告）日：2004-09-02

  The invention relates to compounds that are selective inhibitors of matrix metalloproteinases, to pharmaceutical compositions containing them and to their use in the prevention and/or treatment of MMP-associated diseases. The invention also relates to methods for identification of lead compounds that are selective inhibitors of matrix metalloproteinases. The compounds have the properties that they: (a) bind allosterically to a matrix metalloproteinase or small group of metallic metalloproteinases; (b) bind into at least the S1′ pocket, at least the S1″ pocket (as defined) or at least the S1′ pocket and the S1″ pocket of said matrix metalloproteinase; and (c) exhibit selectivity for a matrix metalloproteinase or group of matrix metalloproteinases other than MMP-13.

  本发明涉及选择性抑制基质金属蛋白酶的化合物，包括含有它们的药物组成物，以及它们在预防和/或治疗与MMP相关的疾病中的应用。本发明还涉及识别选择性抑制基质金属蛋白酶的先导化合物的方法。这些化合物具有以下特性：(a)与基质金属蛋白酶或少量金属金属蛋白酶发生异构作用；(b)至少结合于所述基质金属蛋白酶的S1'口袋、至少结合于S1"口袋（如定义所述）或至少结合于所述基质金属蛋白酶的S1'口袋和S1"口袋；以及(c)表现出选择性，对MMP-13以外的基质金属蛋白酶或基质金属蛋白酶组具有选择性。